Table 2.
Baseline type 2 biomarkers and history of atopic comorbidities
| Age ≥ 60 years | Age < 60 years | |||||||
|---|---|---|---|---|---|---|---|---|
| Placebo qw | Dupilumab 300 mg q2w |
Dupilumab 300 mg qw |
Total | Placebo qw | Dupilumab 300 mg q2w |
Dupilumab 300 mg qw |
Total | |
| Laboratory characteristics | ||||||||
| Total IgE (IU/mL), median (IQR), n |
1665.5 (196.0–6559.0), n = 56 |
1364.5 (71.0–7360.0), n = 54 |
837.0 (123.0–6711.0), n = 73 |
1172.0 (123.0–7338.0)a, N = 183 |
3561.0 (595.0–10,000.0), n = 823 |
3187.5 (625.5–10,000.0), n = 616 |
2825.0 (548.0–10,000.0), n = 817 |
3136.0 (582.0–10,000.0)a, N = 2256 |
| TARC (pg/mL), median (IQR), n |
2629.1 (874.5–9151.5), n = 56 |
2871.5 (936.0–8054.0), n = 54 |
2273.0 (899.7–6655.0), n = 73 |
2602.1 (899.7–7355.0), N = 183 |
2258.7 (915.0–6722.8), n = 821 |
2295.5 (903.0–7011.8), n = 614 |
1943.3 (823.0–5928.0), n = 813 |
2143.3 (883.3–6584.5), N = 2248 |
| History of atopic comorbidities, n (%) | n = 56 | n = 55 | n = 72 | N = 183 | n = 823 | n = 627 | n = 808 | N = 2258 |
| Asthma | 17 (30.4) | 17 (30.9) | 24 (33.3) | 58 (31.7) | 330 (40.1) | 268 (42.7) | 312 (38.6) | 910 (40.3) |
| Allergiesb | 36 (64.3) | 28 (50.9) | 45 (62.5) | 109 (59.6) | 516 (62.7) | 406 (64.8) | 533 (66.0) | 1455 (64.4) |
| Allergic rhinitis | 22 (39.3) | 24 (43.6) | 26 (36.1) | 72 (39.3) | 386 (46.9) | 315 (50.2) | 397 (49.1) | 1098 (48.6) |
| Food allergy | 15 (26.8) | 10 (18.2) | 23 (31.9) | 48 (26.2) | 293 (35.6) | 254 (40.5) | 313 (38.7) | 860 (38.1) |
| Allergic conjunctivitis | 11 (19.6) | 14 (25.5) | 15 (20.8) | 40 (21.9) | 235 (28.6) | 184 (29.3) | 218 (27.0) | 637 (28.2) |
| Hives | 8 (14.3) | 8 (14.5) | 10 (13.9) | 26 (14.2) | 95 (11.5) | 86 (13.7) | 100 (12.4) | 281 (12.4) |
| Chronic rhinosinusitis | 3 (5.4) | 6 (10.9) | 5 (6.9) | 14 (7.7) | 54 (6.6) | 33 (5.3) | 45 (5.6) | 132 (5.8) |
| Nasal polyps | 2 (3.6) | 0 | 3 (4.2) | 5 (2.7) | 18 (2.2) | 13 (2.1) | 22 (2.7) | 53 (2.3) |
| Eosinophilic esophagitis | 0 | 1 (1.8) | 0 | 1 (0.5) | 3 (0.4) | 6 (1.0) | 1 (0.1) | 10 (0.4) |
IgE immunoglobin E, IU international units, IQR interquartile range, mL milliliter, pg picograms, q2w every 2 weeks, qw every week, TARC thymus and activation-regulated chemokine
aSignificant differences in total IgE (IU/mL) were observed between the ≥ 60 and < 60 groups (P = 0.0013)
bAllergies other than food